Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Remission in ankylosing spondylitis.

J Zochling1, J Braun

  • 1Rheumazentrum-Ruhrgebiet, St. Josefs-Krankenhaus, Herne, Germany.

Clinical and Experimental Rheumatology
|November 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Annals of the rheumatic diseases·2002
Same author

[Current status of therapeutic approaches in spondyloarthropathies].

Zeitschrift fur Rheumatologie·2002
Same author

Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.

Rheumatology (Oxford, England)·2002
Same author

Brain areas specific for attentional load in a motion-tracking task.

Journal of cognitive neuroscience·2002
Same author

Infliximab treatment of severe ankylosing spondylitis: one-year followup.

Arthritis and rheumatism·2002
Same author

Magnetic resonance elastography: a method for the noninvasive and spatially resolved observation of phase transitions in gels.

Journal of the American Chemical Society·2001

Achieving remission is a key goal for treating ankylosing spondylitis (AS). New therapies like TNF antagonists offer better control, making remission a realistic aim to prevent long-term damage.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Ankylosing spondylitis (AS) is a chronic inflammatory disease causing pain and disability.
  • Historically, treatments for AS were primarily symptomatic with limited efficacy in severe cases.
  • The advent of TNF antagonists has significantly improved disease management.

Purpose of the Study:

  • To explore the concept of disease remission in ankylosing spondylitis.
  • To review existing remission and low disease activity criteria for AS.
  • To highlight the need for further definition and evaluation of remission as a therapeutic goal in AS.

Main Methods:

  • Review of current literature on ankylosing spondylitis (AS) management and remission criteria.
  • Analysis of existing partial remission criteria developed by the ASsessments in Ankylosing Spondylitis (ASAS) working group.

Related Experiment Videos

  • Examination of empirically defined low disease activity states in anti-tumour necrosis factor (anti-TNF) therapy studies.

    • Main Results:

    • The concept of remission in AS has received limited attention in scientific literature.
    • Existing criteria include ASAS partial remission criteria and empirically defined low disease activity states.
    • Effective therapies like TNF antagonists are making remission an achievable and important goal.

    Conclusions:

    • Remission is an increasingly recognized and appropriate therapeutic goal for ankylosing spondylitis.
    • Defining and evaluating remission criteria is crucial for guiding treatment and potentially modifying disease progression.
    • Further research is needed to establish robust remission criteria for AS.